BERWYN, PA — AscellaHealth has reaffirmed its commitment to Gene Therapy and Specialty Pharmacy Awareness Month for the third year, as recognized by the Society for Health Care Strategy & Market Development (SHSMD) of the American Hospital Association. This observance aims to enhance the understanding of cutting-edge gene therapies and specialty medications for complex and rare conditions.
Dea Belazi, CEO of AscellaHealth, emphasizes the initiative’s significance, stating, “We invite all stakeholders in the specialty pharmaceutical industry to join us in raising awareness and strengthening the understanding of innovative gene therapies and specialty medications for complex, chronic and rare conditions.” The month-long observance serves as a platform to highlight the essential role of patient-centric care in improving treatment outcomes.
AscellaHealth is dedicated to ensuring patients receive timely and appropriate therapies. By collaborating with biopharmaceutical manufacturers, payers, and healthcare providers, they tackle access barriers to costly gene therapies. Their strategic market access initiatives focus on affordability, supply chain efficiency, and utilizing real-world evidence to guide reimbursement decisions.
Belazi continues, “AscellaHealth expects to draw attention to the value of specialty pharmacies, their focus on delivering high-cost medication therapy and providing high touch, coordinated care for patients with these complex conditions.”
To further its impact, AscellaHealth will participate in the Self-Insurance Institute of America, Inc. (SIIA) National Conference in September 2024, where they plan to showcase solutions that help self-insured employers manage specialty drug expenditures while enhancing therapeutic outcomes.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.